The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

Antibiotic-resistant bacteria are a serious public health threat. Understanding the biology of these bacteria—such as how ...

Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

Antibiotic-resistant bacteria is a serious public health threat. Understanding the biology of these bacteria--such as how they synthesise their protective capsules--is essential for developing new ...

PNEUMOVAX 23 contains a mixture of inactive parts from 23 of the most common types of pneumococcal bacteria. PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of ...

Pneumococcal disease is treated with antibiotics. Pneumococcal disease is caused by a bacterium called Streptococcus pneumoniae (pneumococcus). The bacteria enter the body through the nose and mouth, ...

SINGAPORE: Antibiotic-resistant bacteria pose a significant threat to public health, and researchers from the Yong Loo Lin School of Medicine at the National Un ...